"Clinica Ematologica Centro Trapianti e Terapie Cellulari "Carlo Melzi" Azienda Ospedaliero Universitaria "
Welcome,         Profile    Billing    Logout  
 14 Trials 
14 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zaja, Francesco
NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Checkmark [VIRTUAL] A phase II study of acalabrutinib in combination with R-CHOP chemotherapy prior to autologous stem cell transplantation in previously untreated mantle cell lymphoma
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), Klinikum der Universitaet Muenchen
Mantle Cell Lymphoma
05/21
05/26
NCT03764618 / 2018-004774-97: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Checkmark [VIRTUAL] FOSTAMATINIB FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA): UPDATES FROM THE PHASE 2 AND PHASE 3 CLINICAL TRIALS
Checkmark [VIRTUAL] Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study
Checkmark [VIRTUAL] Fostamatinib treatment of warm antibody autoimmune hemolytic anemia: a global, randomized, double-blind, placebo-controlled, phase 3 study
Recruiting
3
90
Europe, Canada, US, RoW
Fostamatinib disodium, R935788, Fostamatinib, Placebo
Rigel Pharmaceuticals
Warm Antibody Autoimmune Hemolytic Anemia
10/21
03/22
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
200
Europe
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
02/23
02/26
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Not yet recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Not yet recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi ONLUS
Follicular Lymphoma
07/28
07/30
NCT01009970 / 2009-012143-42: Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Checkmark P2 data - ASCO
Recruiting
2
50
Europe
Rituximab, Cyclophosphamide, Vincristine, Prednisone, Doxorubicin
Fondazione Italiana Linfomi ONLUS
Diffuse Large B-Cell Lymphoma
05/11
05/12
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS
Mantle Cell Lymphoma
12/20
04/22
NCT04251065: A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin

Recruiting
2
35
Europe
Daratumumab, Darzalex
Fondazione Italiana Linfomi ONLUS
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
03/22
12/23
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Recruiting
2
90
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi ONLUS, Janssen-Cilag S.p.A.
DLBCL
02/23
02/25
LAL2317, NCT03367299 / 2017-004251-23: Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

Recruiting
2
149
Europe
Chemotherapy + Blinatumomab
Gruppo Italiano Malattie EMatologiche dell'Adulto, Amgen S.r.l., A.I.L Associazione Italiana contro le Leucemie
Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor
08/23
08/23
UNIT, NCT01196884: Immune Thrombocytopenia (ITP) Immune-Genetic Assessment

 
N/A
190
Europe
Azienda Sanitaria-Universitaria Integrata di Udine
Thrombocytopenia
 
 
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Recruiting
N/A
15
Europe
Venetoclax, Azacitidine, Decitabine
Ospedale Maggiore Di Trieste
Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax
09/20
09/20
ICI-RT-1, NCT04419441: Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

Recruiting
N/A
12
Europe
Immune checkpoint inhibitor, radiotherapy
Ospedale Maggiore Di Trieste
Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy
09/20
09/20
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Checkmark A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Checkmark COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
Checkmark Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
04/22
04/22

Download Options